These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23562150)

  • 21. The discrepancy between patients and informants on clinician-rated measures in major depressive disorder: implications for clinical trials and clinical practice.
    Peselow ED; Karamians R; Lord M; Tobia G; IsHak WW
    Int Clin Psychopharmacol; 2014 Mar; 29(2):111-5. PubMed ID: 24216755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
    Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
    Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
    Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
    J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning.
    Trivedi MH; Corey-Lisle PK; Guo Z; Lennox RD; Pikalov A; Kim E
    Int Clin Psychopharmacol; 2009 May; 24(3):133-8. PubMed ID: 19318972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.
    Fraguas R; da Silva Telles RM; Alves TC; Andrei AM; Rays J; Iosifescu DV; Wajngarten M
    Contemp Clin Trials; 2009 May; 30(3):205-11. PubMed ID: 19470312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
    Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
    Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data.
    Sakurai H; Suzuki T; Yoshimura K; Mimura M; Uchida H
    Psychopharmacology (Berl); 2017 Aug; 234(16):2453-2461. PubMed ID: 28470399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of BPRS interview length on ratings reliability in a schizophrenia trial.
    Targum SD; Cara Pendergrass J; Toner C; Zumpano L; Rauh P; DeMartinis N
    Eur Neuropsychopharmacol; 2015 Mar; 25(3):312-8. PubMed ID: 25554563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An exploratory study of combination buspirone and melatonin SR in major depressive disorder (MDD): a possible role for neurogenesis in drug discovery.
    Fava M; Targum SD; Nierenberg AA; Bleicher LS; Carter TA; Wedel PC; Hen R; Gage FH; Barlow C
    J Psychiatr Res; 2012 Dec; 46(12):1553-63. PubMed ID: 22998742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol.
    Oakes TM; Myers AL; Marangell LB; Ahl J; Prakash A; Thase ME; Kornstein SG
    Hum Psychopharmacol; 2012 Jan; 27(1):47-56. PubMed ID: 22241678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
    Weisler RH; Montgomery SA; Earley WR; Szamosi J; Lazarus A
    Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A method to quantify rater bias in antidepressant trials.
    Petkova E; Quitkin FM; McGrath PJ; Stewart JW; Klein DF
    Neuropsychopharmacology; 2000 Jun; 22(6):559-65. PubMed ID: 10788756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychometric properties of the Quick Inventory of Depressive Symptomatology (QIDS-SR) in UK primary care.
    Cameron IM; Crawford JR; Cardy AH; du Toit SW; Lawton K; Hay S; Mitchell K; Sharma S; Shivaprasad S; Winning S; Reid IC
    J Psychiatr Res; 2013 May; 47(5):592-8. PubMed ID: 23419617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.
    Zisook S; Lesser IM; Lebowitz B; Rush AJ; Kallenberg G; Wisniewski SR; Nierenberg AA; Fava M; Luther JF; Morris DW; Trivedi MH
    J Clin Psychiatry; 2011 Oct; 72(10):1322-32. PubMed ID: 22075098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationships among pain, depressed mood, and global status in fibromyalgia patients: post hoc analyses of a randomized, placebo-controlled trial of milnacipran.
    Arnold LM; Palmer RH; Gendreau RM; Chen W
    Psychosomatics; 2012; 53(4):371-9. PubMed ID: 22677218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients.
    Trombello JM; Killian MO; Grannemann BD; Rush AJ; Mayes TL; Parsey RV; McInnis M; Jha MK; Ali A; McGrath PJ; Adams P; Oquendo MA; Weissman MM; Carmody TJ; Trivedi MH
    J Psychopharmacol; 2019 Feb; 33(2):185-193. PubMed ID: 30652941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach.
    Tedeschini E; Fava M; Papakostas GI
    J Clin Psychiatry; 2011 Jan; 72(1):98-113. PubMed ID: 21208576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
    Septien-Velez L; Pitrosky B; Padmanabhan SK; Germain JM; Tourian KA
    Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Magnitude of placebo response and response variance in antidepressant clinical trials using structured, taped and appraised rater interviews compared to traditional rating interviews.
    Khan A; Faucett J; Brown WA
    J Psychiatr Res; 2014 Apr; 51():88-92. PubMed ID: 24477068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.